FDA approves Tzield to treat children and adolescents with stage 3 type 1 diabetes

The FDA has granted accelerated approval for teplizumab-mzwv as the first disease-modifying therapy for children and adolescents with stage 3 type 1 diabetes, according to an industry press release. As Healio previously reported, teplizumab-mzwv (Tzield, Sanofi) was originally approved by the FDA in November 2022 to delay stage 3 type 1 diabetes among children and adults with stage 2 disease. In